The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | IberDd in patients with newly diagnosed myeloma: a subgroup analysis by renal function
Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, briefly discusses a subgroup analysis by renal function of the Phase I/II CC-220-MM-001 trial (NCT02773030) evaluating iberdomide plus daratumumab and dexamethasone (IberDd) in patients with newly diagnosed multiple myeloma (MM). The analysis suggests that the presence of renal insufficiency does not affect clinical outcomes when treating this patient population with the IberDd regimen. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
You know, Iber-Dara-Dex is part of a cohort of the original phase one study in newly diagnosed transplant ineligible patients is really an exciting data set. And I think it’s exciting because the depth of response and the MRD negativity as I showed at IMS this year is acturally more than double what was seen in MAIA. So the activity, the additional benefit of using iberdomide over lenalidomide is not just there in terms of adverse events, but it’s actually efficacy as well...
You know, Iber-Dara-Dex is part of a cohort of the original phase one study in newly diagnosed transplant ineligible patients is really an exciting data set. And I think it’s exciting because the depth of response and the MRD negativity as I showed at IMS this year is acturally more than double what was seen in MAIA. So the activity, the additional benefit of using iberdomide over lenalidomide is not just there in terms of adverse events, but it’s actually efficacy as well. What we also noticed is that using it in patients with renal insufficiency is not a problem, not a challenge. And in fact, the benefit was the same, whether patients had normal renal function or some level of renal dysfunction, which in an elderly patient population is a really important metric to understand.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
